Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Global Stress Management Industry Report - Featuring Abbott Laboratories, Alkermes & Allergan Among Others

The "Stress Management Industry: Global Trends" report has been added to ResearchAndMarkets.com's offering.

ABT : 80.70 (-0.81%)
ALKS : 19.69 (-2.81%)
AGN : 192.16 (-0.53%)
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m....

ALKS : 19.69 (-2.81%)
Alkermes Plc has the Best Relative Performance in the Biotechnology Industry (ALKS , AKBA , CLVS , ARDX , BLUE )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AKBA : 8.42 (-4.64%)
ALKS : 19.69 (-2.81%)
CLVS : 7.11 (-4.95%)
SmarTrend Watching for Potential Pullback in Shares of Alkermes Plc After 5.30% Gain

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $18.70 to a high of $19.75. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $18.82...

ALKS : 19.69 (-2.81%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CLVS , ALKS , PBYI , AKBA , AMAG )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 19.69 (-2.81%)
CLVS : 7.11 (-4.95%)
PBYI : 10.27 (-3.20%)
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26, 2020 at 9:00 a.m. ET (2:00 p.m. GMT)...

ALKS : 19.69 (-2.81%)
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

BIIB : 319.17 (-2.53%)
JNJ : 142.04 (-1.14%)
ALKS : 19.69 (-2.81%)
GH : 80.69 (-0.99%)
Watch for Alkermes Plc to Potentially Rebound After Falling 5.81% Yesterday

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $17.93 to a high of $19.97. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $18.80...

ALKS : 19.69 (-2.81%)
Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat Estimates

Alkermes beats earnings and sales estimates in the fourth quarter of 2019.

ALKS : 19.69 (-2.81%)
Alkermes: 4Q Earnings Snapshot

DUBLIN (AP) _ Alkermes PLC (ALKS) on Thursday reported a loss of $5.4 million in its fourth quarter.

ALKS : 19.69 (-2.81%)
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.

ALKS : 19.69 (-2.81%)
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?

We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.

BIIB : 319.17 (-2.53%)
ALKS : 19.69 (-2.81%)
NKTR : 21.16 (-1.17%)
ASND : 128.24 (-1.17%)
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss the company's fourth quarter and year-end 2019 financial...

ALKS : 19.69 (-2.81%)
Alkermes Plc is Among the Companies in the Biotechnology Industry with the Best Relative Performance (ALKS , CLVS , ATRA , FOLD , SGEN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 19.69 (-2.81%)
ATRA : 11.59 (+3.76%)
CLVS : 7.11 (-4.95%)
Lieff Cabraser Files California Wrongful Death Case Against Alkermes Over Vivitrol Opioid Dependence Drug

Lieff Cabraser has filed a wrongful death lawsuit against biopharmaceutical manufacturer Alkermes, Inc. on behalf of the family of California resident Clayton Stafford relating to Clayton's mandated prescription...

ALKS : 19.69 (-2.81%)
Alkermes Plc Set to Possibly Rebound After Yesterday's Selloff of 2.35%

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $16.99 to a high of $17.56. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $17.08...

ALKS : 19.69 (-2.81%)
7.3% Return Seen to Date on SmarTrend Alkermes Plc Call (ALKS)

SmarTrend identified a Downtrend for Alkermes Plc (NASDAQ:ALKS) on January 6th, 2020 at $19.22. In approximately 3 weeks, Alkermes Plc has returned 7.34% as of today's recent price of $17.81.

ALKS : 19.69 (-2.81%)
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review

The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.

LLY : 133.08 (-0.34%)
AGN : 192.16 (-0.53%)
JNJ : 142.04 (-1.14%)
ALKS : 19.69 (-2.81%)
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831 (olanzapine/samidorphan)...

ALKS : 19.69 (-2.81%)
Look for Shares of Alkermes Plc to Potentially Rebound after Yesterday's 4.48% Sell Off

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $17.38 to a high of $18.46. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $18.12...

ALKS : 19.69 (-2.81%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -2.11 , SEDG -5.23 , THC -0.09 , TER -2.17 , LITE -2.33
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar